Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 266Neoplasms 231Carcinoma, Non-Small-Cell Lung 209Colorectal Neoplasms 155Prostatic Neoplasms 148Lung Neoplasms 121Neoplasm Metastasis 112Ovarian Neoplasms 105Multiple Myeloma 98Pancreatic Neoplasms 91Leukemia, Myeloid, Acute 82Squamous Cell Carcinoma of Head and Neck 76Endometrial Neoplasms 67Melanoma 66Stomach Neoplasms 63Glioblastoma 61Recurrence 58Brain Neoplasms 56Carcinoma, Hepatocellular 53Urinary Bladder Neoplasms 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Head and Neck Neoplasms 51Carcinoma, Renal Cell 51Triple Negative Breast Neoplasms 50Lymphoma 50Hematologic Neoplasms 47Glioma 46Esophageal Neoplasms 46Colonic Neoplasms 46Small Cell Lung Carcinoma 43

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Muscle Invasive Bladder Urothelial Carcinoma × 30 days × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡